MedTrace Logo

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

NCT01991795 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 19271

Last updated 2020-03-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Ticagrelor 60 mg

Ticagrelor 60 mg bd taken orally as tablets

DRUG

Ticagrelor placebo

Ticagrelor placebo bd taken orally as tablets

Sponsors & Collaborators

Principal Investigators

  • Philippe Gabriel Steg, MD · Hôpital Bichat-Claude Bernard 46 Rue Henri Huchard, Paris

  • Deepak L. Bhatt, MD · Brigham and Women's Hospital75 Francis Street, Boston

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-10
Primary Completion
2019-01-25
Completion
2019-01-25

Countries

  • United States
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong
  • Hungary
  • India
  • Israel
  • Italy
  • Japan
  • Mexico
  • Netherlands
  • Norway
  • Peru
  • Philippines
  • Poland
  • Puerto Rico
  • Romania
  • Russia
  • Saudi Arabia
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01991795 on ClinicalTrials.gov